Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics
(NQ:
SRPT
)
140.49
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
June 06, 2024
These are the overvalued stocks to sell. They represent quality companies that are worth buying after a 20% to 30% downside
Via
InvestorPlace
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
May 31, 2024
Via
Benzinga
Why Sarepta Therapeutics Stock Is Rising Today
May 30, 2024
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Analysts Have This To Say About Sarepta Therapeutics
May 20, 2024
Via
Benzinga
What Analysts Are Saying About Sarepta Therapeutics Stock
May 02, 2024
Via
Benzinga
Sarepta Downgraded As FDA Decision Date Approaches, Shares Up 50% Over Last Six Months
May 28, 2024
RBC Capital Markets downgrades Sarepta Therapeutics following increased FDA label expansion expectations for Elevidys and recent stock surge.
Via
Benzinga
Exposures
Product Safety
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 28, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
May 24, 2024
Via
Benzinga
The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now
May 23, 2024
With interest cuts on the horizon, it's a prime time to consider these high-risk-high-reward biotech stocks to buy.
Via
InvestorPlace
Jim Cramer: This Industrial Stock Is Doing 'Very Well'; Here's His Take On Palantir
May 22, 2024
Jim Cramer likes Enbridge Inc. (NYSE: ENB), says Lazard, Inc. (NYSE: LAZ) is a good buy, and Advanced Drainage Systems, Inc. (NYSE: WMS) is an incredible infrastructure play. He also mentions Jacobs...
Via
Benzinga
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
May 20, 2024
Dyne Therapeutics is looking to take on Sarepta Therapeutics in DMD.
Via
Investor's Business Daily
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
May 04, 2024
Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments.
Via
InvestorPlace
Exposures
Product Safety
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
May 03, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Apple, Kellanova And 3 Stocks To Watch Heading Into Thursday
May 02, 2024
Via
Benzinga
SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 01, 2024
SRPT stock results show that Sarepta Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
May 01, 2024
SRPT earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
May 01, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
1 Top Growth Stock to Buy and Hold for 10 Years
May 01, 2024
This company's lineup might look very different in a decade, but the end result will be the same for investors.
Via
The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 30, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Stock Shows Improved Technical Strength
April 29, 2024
The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73.
Via
Investor's Business Daily
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
April 24, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
April 08, 2024
Sarepta stock has taken a beating this year, and it might not be over with the first-quarter report looming.
Via
Investor's Business Daily
2 Biotech Stocks to Buy Hand Over Fist in April
April 06, 2024
These drugmakers have made important moves over the past year.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
April 04, 2024
Via
Benzinga
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
March 28, 2024
The company could follow Sarepta Therapeutics with a gene therapy for Duchenne muscular dystrophy.
Via
Investor's Business Daily
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
March 13, 2024
The threat is still emerging, but it could be significant.
Via
The Motley Fool
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
March 08, 2024
REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients.
Via
Benzinga
Got $1,000? Buy These Hot Growth Stocks Before They Take Off.
March 08, 2024
These stocks haven't been able to get much traction lately, even though they clearly deserve to now.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.